Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sernova (TSE:SVA)
TSX:SVA
Sernova (SVA) Stock Price & Analysis
94 Followers
SVA Stock Chart & Stats
Day’s RangeC$0.43 - C$0.45
52-Week Range― - ―
Previous CloseC$0.45
Volume87.72K
Average Volume (3M)N/A
Market Cap
C$133.47M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Jun 26, 2024EPS Estimate
-C$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.50Price Target Upside695.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Sernova News
PremiumCompany Announcements
Sernova Corp Announces Major Organizational Changes
PremiumCompany Announcements
Sernova Strengthens Board with Evotec’s Expert
PremiumCompany Announcements
Sernova Reports Breakthrough in Diabetes Treatment
PremiumCompany Announcements
Sernova Corp Appoints Interim CFO, Advances Innovation
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe first patient treated in Cohort 1 has reached four years of insulin independence and normalized HbA1c.
Management Team StrengthAppointment of Nicholas Rossettos as Interim CFO adds experienced financial leadership.
Product AdvancementCell Pouch continues to show promise in T1D; device platform looks to target additional endocrine disorders.
Bears Say
Financial PerformanceSernova reported FQ423 results that missed estimates due to unexpectedly high R&D expenses.
Financial PositionSVA's current cash balance suggests a potential need for a capital raise in the near future.
Operational ChallengesKey management changes at SVA due to alleged personal misconduct could introduce uncertainty.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.82% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
96.17% Public Companies and
Individual Investors
SVA FAQ
What was Sernova’s price range in the past 12 months?
Currently, no data Available
What is Sernova’s market cap?
Currently, no data Available
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Jun 26, 2024 which is in 57 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Mar 18, 2024. The company reported -C$0.03 earnings per share for the quarter, the consensus estimate of -C$0.03 by C$0.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Undervalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is -C$0.03.
How many shares outstanding does Sernova have?
Currently, no data Available
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.03 in its last earnings report, expectations of -C$0.03. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
---
Sernova Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.29%
12-Months-Change
Fundamentals
Return on Equity
-183.58%
Trailing 12-Months
Asset Growth
-60.45%
Trailing 12-Months
Company Description
Sernova
Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. It develops a commercially-viable treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted, prevascularized and scalable medical device.
---
SVA Stock 12 Months Forecast
Average Price Target
C$3.50
▲(695.45% Upside)
Technical Analysis
Best Analysts Covering SVA
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+150.54%
reiterated a buy rating 10 months ago
Copying Douglas Loe's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +150.54% per trade.
---